Albert Bourla, Pfizer CEO (Christopher Goodney/Bloomberg via Getty Images)

As GSK is forced to slam the brakes, Pfiz­er cruis­es ahead with a ‘break­through’ on RSV

Pfiz­er was a late ar­rival to the heavy­weight Phase III fight to gain a first ap­proval for an RSV vac­cine, but the phar­ma gi­ant has shown plen­ty of promise in mak­ing up lost time. And they’re kick­ing up their heels as ri­val Glax­o­SmithK­line has to suf­fer through a clin­i­cal hold that presents a se­ri­ous set­back for their own ef­forts.

The multi­na­tion­al play­er, which has en­joyed a moth­er lode of re­wards from its Covid-19 fran­chise, just picked up break­through ther­a­py des­ig­na­tion sta­tus for its late-stage play here. A BTD is cer­tain­ly no guar­an­tee of suc­cess, but the chance to keep all doors at the FDA wide open as it makes its way through their piv­otal tri­al of­fers the pos­si­bil­i­ty of a faster ap­proval — and that car­ries some big re­wards when you’re up against a GSK or J&J, which al­so has its own con­tender in the fight.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.